This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
 

Adverse Event management and identification

 

Patient assets

 

Other resources

KEYTRUDA in renal cell carcinoma (RCC) resources

Prescribing Information (Great Britain) Prescribing Information (Northern Ireland) [External links]

KEYTRUDA in advanced urothelial carcinoma resources

Prescribing Information (Great Britain) Prescribing Information (Northern Ireland) [External links]

KEYTRUDA in first-line metastatic head & neck squamous cell carcinoma (HNSCC) resources

Prescribing Information (Great Britain) Prescribing Information (Northern Ireland) [External links]

KEYTRUDA in locally advanced unresectable or metastatic oesophageal cancer resources

Prescribing Information (Great Britain) Prescribing Information (Northern Ireland) [External links]

KEYTRUDA in metastatic colorectal cancer (CRC) resources

Prescribing Information (Great Britain) Prescribing Information (Northern Ireland) [External links]

KEYTRUDA in metastatic non-small cell lung cancer (NSCLC) resources

Prescribing Information (Great Britain) Prescribing Information (Northern Ireland) [External links]

KEYTRUDA in the adjuvant treatment of melanoma resources

Prescribing Information (Great Britain) Prescribing Information (Northern Ireland) [External links]

KEYTRUDA in triple-negative breast cancer (TNBC) resources

Prescribing Information (Great Britain) Prescribing Information (Northern Ireland) [External links]

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-PDO-02020 | Date of Preparation: May 2022